Observations from the Chair
-
The technology is sound
-
Solid barriers to entry as evidenced by our partners’ willingness to engage
-
Shareholder sentiment at an all time low
-
Investor communications must be improved & confidence restored
-
Company’s business model is not well understood
-
Some investor’s expectations are not aligned with the reality of the business
-
Many investors fail to recognise that raising capital is an intrinsic feature of life science companies
-
Long lead times are part of the business model notwithstanding the accelerated pathway of 505(b)(2) drug development takes time
-
Need to revitalise management
For more information, download the attached PDF.
Download this document
